At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments such as Fingolimod for validation This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.

Designing robust preclinical studies that deliver accurate data the first time. Building flexibility into plans to prevent delays when priorities shift. Coordinating ADME, PK/PD, and toxicology in parallel to save weeks. With over 16,000 projects conducted successfully, work with a proven partner from early discovery to regulatory submission. Our tailored, quality-driven approach keeps your programme on track and your milestones within reach. Let’s make your IND deadline a milestone you hit with confidence